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Abstract
Potential transmission of hepatitis C virus (HCV) in a private dental practice provides a stark 
reminder that dental healthcare providers (DHCPs) need updated information about this pathogen. 
As DHCPs will likely treat persons with current infection, training on the science of HCV 
infection is useful. Furthermore, in the past five years, our understanding of HCV has evolved. The 
elevated prevalence of chronic HCV infection among “baby boomers” born during 1945–1965 has 
prompted new national screening guidelines. New therapeutic options are revolutionizing HCV 
infection. This review summarizes information about the natural history and epidemiology of 
hepatitis C, describes new CDC screening guidelines and current treatment. In addition it provides 
an overview of how outbreaks of healthcare-associated HCV are detected and prevented. There are 
useful references and websites where additional detail is available for those interested in learning 
more.
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BACKGROUND
Prompted by the potential transmission of hepatitis C virus (HCV) in a private dental 
practice in 2013,1 this review brings dental healthcare providers (DHCPs) up-to-date with 
the natural history and epidemiology, new CDC screening guidelines,2,3 new treatment, 
surveillance, and healthcare-associated HCV transmission and prevention options. The 
review provides useful references and websites where additional detail is available for those 
interested in learning more.
Even before HCV was identified in the late 1980s, the observation that not all transfusion-
associated hepatitis was associated with hepatitis A or B lead to the label ‘non-A, non-B’ 
hepatitis.4 Since then, our understanding of the virus and the development of treatments for 
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infected persons have evolved rapidly. HCV is an RNA virus with great molecular 
heterogeneity within and across individuals, since mutations occur frequently during 
replication. Viral diversity is one of the challenges to vaccine development; others include 
the lack of a non-primate animal model and the unclear immune responses that lead to viral 
clearance.5 There are six major genotypes of HCV with variability by geographic 
distribution; the majority of isolates (about 85%) in the US are genotype 1a or 1b.4
Transmission
HCV is transmitted most efficiently by the parenteral route, and this may occur at even low 
levels of viral contamination. From 2008–2012 CDC received notice of 15 outbreaks of 
healthcare associated transmission of HCV in non-dental ambulatory care settings.6 In 
general, transmission of infectious agents in healthcare settings can occur from patient to 
patient (e.g. due to improper injection practices) patient to provider (e.g. from needle sticks), 
or provider to patient (e.g. during surgery). The risk of transmission depends on factors 
related to the agent, the host, and the environment. HCV can survive in the environment for 
16 hours on a dry surface,7 in water at low temperatures for up to 5 months,8 and can be 
detected in saliva.9 Disinfectants that inactivate hepatitis B virus will also kill HCV on 
environmental surfaces,10 and commercial hand antiseptics are effective at inactivating the 
virus from hands.8
The estimated risk of infection with HCV from a percutaneous injury is about 2%;11 that is, 
greater than with HIV, but less than with hepatitis B virus. Standard Precautions12 for 
injection safety remain the foundation for prevention of healthcare associated hepatitis 
infections, with new toolkits and resources available (Table 1).
Before 1992, and the availability of testing to screen blood and blood products, healthcare 
transmission in the form of blood transfusions was associated with about 15–20% of HCV 
infections.13 In the US, injecting drug use is currently the most frequent risk behavior 
associated with HCV infection.14,15 Of recent concern are clusters of HCV among young 
non-urban adults injecting drugs, who often started injecting cheaper heroin when their 
access to prescription opiods was no longer available.16,17 Sexual transmission is rare except 
under high risk sexual practices.18 Likewise, no infections have been reported associated 
with commercial tattoos and piercing, but transmission may occur in unregulated 
environments (e.g., prisons).19
Burden of disease
DHCPs can reasonably expect to encounter patients with HCV infection, since about 1.6% 
of the US population has ever been infected.20 While about 20% of infections resolve 
spontaneously,21 most infected persons develop chronic infection (defined as an HCV-RNA 
positive test result from plasma or serum). CDC estimated in 2002 that 3.2 million persons 
(1.3%) in the US were HCV-RNA positive. Prevalence of chronic infection is higher 
(3.25%) among persons born during 1945–1965.22 About 60% of dentists are in this cohort 
(‘baby boomers’)23 and may have undetected past or current infection themselves; another 
reason for DHCPs to be knowledgeable about hepatitis C.
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Acute infection is symptomatic in about 50% of cases, fewer (10%) among persons infected 
through injection drug use.24 When symptoms are present, these are non-specific and can 
include jaundice, fever, abdominal pain, malaise, and elevated liver function tests (alanine 
aminotransferase (ALT) or aspartate aminotransferase (AST)). Many (about 50%) are 
unaware of their infection status.25 Among persons with chronic infection, about 15–30% 
may progress to liver cirrhosis,13 and of these patients, an estimated 1–3% will develop 
hepatocellular carcinoma.26 Currently, HCV is the leading indication for liver 
transplantation, costing a median of $120,500 per hospitalization.27 Deaths associated with 
HCV infection surpassed deaths with HIV infection in 2007.28
Screening, Diagnosis, and Treatment
Until 2012, screening for HCV infection was recommended for persons at highest risk of 
infection (i.e., injection drug users, persons with medical conditions that required dialysis or 
transfusions, recipients of organs or transfusions before 1992) or with a known exposure to 
HCV (i.e., children born to HCV-positive women and occupationally exposed persons).29 
Current age-based screening recommendations have recently expanded the recommendation 
to include a one-time test for all persons born between 1945–1965, with alcohol use 
screening and referral to care for infected persons.22
Diagnosis in public health settings and primary care begins with the detection of antibody 
against HCV (anti-HCV).3 Rapid tests are now available with high sensitivity and 
specificity; these use blood from either a fingerstick capillary or whole blood from 
venipuncture and provide results in <40 minutes.30 The majority of anti-HCV tests are 
immunoassays. Immunoassays can determine whether or not someone has ever been 
infected with HCV, but only a nucleic acid test to detect HCV-RNA whether a person has 
current infection.3 HCV-RNA tests can be qualitative (positive or negative) or quantitative 
(viral copies/mL). The genotype test is another type of nucleic acid test, which may be 
performed during evaluation for treatment.31
Not all infected persons are diagnosed and treated. Data from a CDC cohort was combined 
with a nationally representative survey to determine the number of infected persons who 
have been diagnosed and are receiving appropriate care.32 Of the estimated 3.2 million US 
residents currently infected, only about 50% have been diagnosed. Of these, about 32–38% 
have been referred to care, 7–11% treated, and 5–6% cured. However, new screening 
recommendations should identify more asymptomatic infections,2 at a time when there are 
great improvements in treatment protocols and outcomes.33
Until 2011, the standard of care consisted of pegylated interferon plus ribavirin.26 This 
regimen required weekly injections, had only about a 50% success rate for genotype 1, and 
had frequent side effects. Since then, the protease inhibitors telaprevir and boceprevir have 
been introduced, still in conjunction with interferon and ribavirin, but with greater success 
rates.34 In 2013, sofosbuvir, used in the first interferon-free treatment regimens, was 
submitted for FDA approval. These and other therapies currently in clinical trials are already 
revolutionizing the treatment of chronic HCV infection.35
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SURVEILLANCE
Surveillance for HCV in the US
National surveillance is conducted for two discrete HCV events: acute disease and past/
present hepatitis C infection (i.e., includes persons with current chronic infection and history 
of infection). The surveillance case definition for acute disease requires a combination of 
symptoms and laboratory findings, but for past/present disease, only laboratory findings are 
required. In 2012, surveillance defined acute HCV infection as illness with 1) discrete onset 
of symptoms (e.g., nausea, anorexia, fever, malaise, or abdominal pain) and 2) jaundice or 
elevated serum ALT levels (> 400 IU/L). There is also an option to identify a new 
seroconversion as an acute case; this requires only one positive test with a previous negative 
within the past 6 months.15 With advances in information technology, most health 
departments have developed electronic, laboratory-initiated reporting to conduct routine 
surveillance for viral hepatitis cases more efficiently.
Flow of surveillance information
HCV infection is a reportable condition in most states.14 Providers, facilities and 
laboratories are usually required to report, but in practice, most cases are identified first from 
laboratory-initiated reporting. Local and state health departments receive the reports and 
check to determine whether the case was previously reported or represents a new case.36 
Health departments conduct investigations of reports, depending on available resources, and 
submit these to CDC weekly (Figure).
When a person with HCV infection is determined to represent a new, acute case, health 
departments pursue supplemental clinical and demographic data; however, in practice, 
resources frequently limit the number of cases investigated. Investigators also assess risk 
factors for infection by identifying exposures during the incubation period (2 weeks – 6 
months before symptom onset). Among the potential exposures, health departments collect 
history of accidental needlestick, outpatient injections, employment in the medical or dental 
field, hospitalization, surgery, and dental work or oral surgery.
Data from HCV surveillance are used to describe burden of disease and characteristics of 
infected populations. Reports are disseminated on-line and in scientific venues to guide 
prevention and plan for healthcare resource needs at the state and national level.14
Healthcare-Associated Outbreak Detection and Investigation
It is frequently a telephone call from an astute clinician, who diagnoses HCV infection in a 
person with no behavioral risk factors or sees an unexpectedly high number of infections in a 
short period of time (e.g., 2–3 cases in 2 weeks compared to no cases for months), that leads 
to an investigation.
At the health department, follow-up of potential healthcare transmission of HCV typically 
begins by confirming whether infection indeed occurred. Then, surveillance investigators 
assess all potential exposures within the incubation period, including, if appropriate, a 
relative measure of the risk of healthcare transmission. Once the report is received, health 
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department officials face many barriers to conducting investigations.37 If the investigation 
identifies risky infection control practices, patients potentially exposed during the at-risk 
time period are notified to seek testing. There have been over 90,000 at-risk persons notified 
to seek HCV testing associated with the 16 outbreaks reported to CDC from 2008–2012. 
CDC developed a ‘Healthcare Investigation Guide’ to support health departments in their 
efforts to quickly identify transmission of infection and control any unsafe clinical practices 
(Table 1).
Health department personnel often work in collaboration with CDC during HCV 
investigations, especially in the area of laboratory support. Genetic sequencing is used to 
assign virus isolated from different individuals into related clusters by their degree of 
relatedness.37 For example, in an investigation of HCV transmission in an endoscopy clinic, 
molecular characterization confirmed a very high degree of similarity between 2 source 
patients with chronic HCV infection and 7 patients infected at the clinic.38 Laboratory 
analyses are, and must be, conducted and interpreted as a component of a larger 
epidemiologic investigation.
Reported Healthcare-Associated HCV Outbreaks
From 2008–2012, CDC received notice of 16 outbreaks of healthcare-associated 
transmission of HCV; 15 of these were in ambulatory care settings.6 Combined, these 
outbreaks identified 160 outbreak-associated, confirmed infections. Five of these outbreaks 
were likely associated with syringe reuse, three were associated with drug diversion (i.e., 
when a prescription medication is used by an infected healthcare worker with subsequent 
contamination of the medication vial or syringe), six were in hemodialysis settings, and in 
one outbreak, there were no identified lapses in infection control observed during the 
investigation. Currently, the Oklahoma Health Department is collaborating with CDC in 
investigating the first potential transmission of HCV in a dental setting, specifically in an 
oral surgery practice. Further detail is available on-line.1 CDC maintains an updated list of 
viral hepatitis outbreaks associated with healthcare, as well as links to toolkits for 
investigation of healthcare-associated infections, on an easy to remember website: 
“CDC.gov/hepatitis/Outbreaks.”39
Because of the long incubation period (up to 6 months) and typically asymptomatic course 
of acute HCV infection, many are missed by routine surveillance. Therefore it is likely that 
only a fraction of such outbreaks that occurred have been detected. Asymptomatic infections 
frequently go undetected for many years, leading to under-reporting of cases to the health 
department and difficulty in identifying a healthcare encounter where transmission may have 
taken place. Furthermore, even persons with HCV-related symptoms might not recognize 
them and seek medical attention, or the clinician might not suspect HCV infection. Even if 
diagnosed, HCV infections might not be reported to the health department because clinicians 
might not understand when, how or what to report. Personnel, resource and legal barriers 
may prevent state and local health departments from thoroughly investigating clusters and 
reporting to CDC.37 There is also under-recognition of the potential for healthcare as a risk 
factor for viral hepatitis transmission, so the numbers reported to CDC likely underestimate 
the number of outbreak-associated cases and the number of at-risk persons notified for 
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screening. CDC has developed numerous tools and questionnaires to support health 
departments in investigating potential outbreaks of healthcare-associated infections.39,40
PREVENTION
There is currently no vaccine for primary prevention of hepatitis C. Standard Precautions 
remain the foundation to protect against transmission of HCV and other infectious agents 
during patient care in the dental setting. Original infection control guidelines for dental 
offices were published in 2003,41 and these are the same basic principles and evidence base 
for all outpatient settings. In 2011, CDC developed a new tool outlining the minimum 
expectations for safe care in outpatient settings. The tool is a document that packages basic 
information as a general reference, from which more detailed documents can be accessed 
quickly and easily.42
Standard Precautions for dental and other outpatient settings are summarized in Table 2. 
These include hand hygiene, proper use of personal protective equipment (i.e., gloves, mask, 
gowns), safe handling of sharps and injection practices, environmental cleaning, proper use 
of medical equipment and drugs (e.g., reusable vs. single-use), and respiratory hygiene/
cough etiquette (i.e., use of measures to contain respiratory secretions of symptomatic 
persons and education of healthcare workers to prevent spread of respiratory secretions). 
CDC provides many resources for DHCPs (Table 1) including continuing education training 
for healthcare providers and materials to train staff in infection control.
Injection Safety
Safe injection practices are a part of Standard Precautions. Most HCV transmissions in 
outpatient healthcare settings have been attributed to syringe reuse or other practices that led 
to contamination of the solution or medication intended to be injected43 (e.g., fentanyl, 
propofol). Medications should never be administered to more than one patient using the 
same syringe, even if the needle is changed. In other words, medication vials should not be 
entered with a used syringe or needle. Single-use vials should never be used for more than 
one patient.43
Post-exposure Management of Exposed Healthcare Workers
If, despite prevention efforts, a needlestick or other exposure to HCV occurs, it is important 
to have a protocol to follow. Briefly, CDC’s recommended follow-up11 of exposed 
healthcare workers consists of baseline HCV antibody testing of both the exposed healthcare 
worker and the source patient. In addition, the healthcare worker should have a baseline 
assessment of ALT activity. Follow-up testing of the exposed healthcare worker should be 
performed (e.g., at 4–6 months). HCV-RNA may also be tested at 4–6 weeks if earlier 
diagnosis is desired. Immunoglobulin is not recommended for post-exposure protection.11
Recent recommendations for the management of hepatitis B infected healthcare workers did 
not address the issue of HCV-infected healthcare workers.44 However, The Society for 
Healthcare Epidemiology of America (SHEA) recommends that HCV infected healthcare 
workers with high circulating viral burden (≥104 genome equivalents/mL) follow certain 
precautions and abstain from performing certain invasive procedures. According to SHEA 
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guidelines, HCV-infected HCWs with <104 genome equivalents/mL of circulating virus 
should have routine follow up with a personal physician and maintain consultation with an 
infection control expert to ensure appropriate infection control practices are used.45
Oversight of Infection Control Practices
In hospitals and some outpatient healthcare settings the Centers for Medicare and Medicaid 
Services (CMS) require periodic reports of quality measures from many types of facilities 
receiving reimbursement for services (e.g., ambulatory surgical centers, hemodialysis 
facilities). CMS routinely conducts audits and surveys of facilities through regional offices. 
CDC collaborates with CMS because both agencies are concerned with patient safety and 
preventing healthcare-associated infections (e.g., coverage with vaccination for hepatitis B 
among hemodialysis patients and healthcare workers). For example, CDC developed an 
infection control audit tool to help ambulatory surgical centers prepare for CMS audits. 
Importantly, facilities that demonstrate adherence to CDC infection control guidelines 
receive CMS financial incentives. Currently, no such oversight exists for monitoring 
infection control practices in dental settings.
Summary
The first investigation of HCV transmission in a dental setting serves as a reminder to 
educate DHCPs about hepatitis C. An estimated 3.2 million persons have chronic HCV 
infection in the US, most are asymptomatic. HCV transmission in healthcare settings is 
preventable by the use of Standard Precautions, including injection safety. New tools are 
available to support health departments in conducting investigations, and for providers to 
easily access to information on infection control. Because DHCPs will likely treat persons 
with current or past infection, training on the evolving science of HCV infection could be of 
substantial value.
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Table 1
Resources for dental healthcare practitioners to learn more about hepatitis and other infections that can be 
transmitted during healthcare services.
Resource Location Description
Outbreak investigations in the US 
notified to CDC
http://www.cdc.gov/hepatitis/Outbreaks/HealthcareHepOutbreakTable Listing of investigations of 
healthcare transmission of 
hepatitis B or C, including 
links to references.
Injection safety www.cdc.gov/injectionsafety Continuing education, 
slides, campaign materials.
Outpatient guide and checklist www.cdc.gov/HAI/settings/outpatient-settings.html Integrates information from 
other sources to prevent 
infections in ambulatory 
care settings.
Guidelines and recommendations 
for preventing healthcare associated 
infections
http://www.cdc.gov/HAI/prevent/prevent_pubs.html Links to detailed documents 
for infection control 
including hand hygiene and 
standard precautions.
Healthcare Investigation Guide www.cdc.gov/hepatitis/Outbreaks/HealthcareInvestigationGuide.html Step by step approach to 
investigate possible 
healthcare transmission of 
hepatitis B and C, intended 
for State and local health 
departments.
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Table 2
Summary of Standard Precautions to prevent transmission of infectious agents during patient care in outpatient 
settings
Component Recommendations
Hand hygiene After touching blood, body fluids, secretions, excretions, contaminated items; immediately 
after removing gloves; between patient contacts
Personal protective equipment (PPE)
Gloves For touching blood, body fluids, secretions, excretions, contaminated items; for touching 
mucous membranes and nonintact skin
Mask, eye protection, face shield During procedures and patient-care activities likely to generate splashes or sprays of blood, 
body fluids, secretions
Gown During procedures and patient-care activities when contact of clothing/exposed skin with 
blood/body fluids, secretions, and excretions is anticipated
Soiled patient-care equipment Handle in a manner that prevents transfer of microorganisms to others and to the 
environment; wear gloves if visibly contaminated; perform hand hygiene
Environmental infection control Develop procedures for routine care, cleaning, and disinfection of environmental surfaces, 
especially frequently touched surfaces in patient-care areas
Textiles (linen and laundry) Handle in a manner that prevents transfer of microorganisms to others and to the environment
Needles and other sharps Do not recap, bend, break, or hand-manipulate used needles; use safety features when 
available; place used sharps in puncture-resistant container
Injection safety Never administer medications from the same syringe to more than one patient; do not enter a 
medication vial with a used needle or syringe; never use single-dose vials for more than one 
patient; follow proper infection control practices during administration of injected 
medications
Respiratory hygiene/cough etiquette
(source containment of infectious 
respiratory secretions in symptomatic 
patients, beginning at initial point of 
encounter)
Instruct symptomatic persons to cover mouth/nose when sneezing/coughing; use tissues and 
dispose in no-touch receptacle; observe hand hygiene after soiling of hands with respiratory 
secretions; wear surgical mask if tolerated or maintain spatial separation, > 3 feet if possible
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